CAR-T Cell Therapies From the Transfusion Medicine Perspective.

Abstract

The use of chimeric antigen receptor (CAR)-T cell therapy for the treatment of hematologic malignancies has generated significant excitement over the last several years. From a transfusion medicine perspective, the implementation of CAR-T therapy as a potential mainstay treatment for not only hematologic but also solid-organ malignancies represents a significant opportunity for growth and expansion. In this review, we will describe the rationale for the development of genetically redirected T cells as a cancer therapeutic, the different elements that are required to engineer these cells, as well as an overview of the process by which patient cells are harvested and processed to create and subsequently validate CAR-T cells. Finally, we will briefly describe some of the toxicities and clinical efficacy of CAR-T cells in the setting of patients with advanced malignancy.

DOI: 10.1016/j.tmrv.2016.03.001

3 Figures and Tables

Cite this paper

@article{Fesnak2016CARTCT, title={CAR-T Cell Therapies From the Transfusion Medicine Perspective.}, author={Andrew D. Fesnak and Chieyu Lin and Donald L Siegel and Marcela V Maus}, journal={Transfusion medicine reviews}, year={2016}, volume={30 3}, pages={139-45} }